The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial
Authors:
- 1 August 1999
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 14 (8) , 2139-2142
Abstract
Misoprostol is effective for cervical priming prior to vacuum aspiration for first trimester termination of pregnancy. Previous studies showed that the oral route was more acceptable to patients but there were higher incidences of side-effects when compared with the vaginal route. This study is to determine the optimal dosage and route of administration of misoprostol for pre-operative cervical dilatation. A double-blind, randomized trial was undertaken for 225 nulliparous women with 8-12 weeks amenorrhoea. They were randomly assigned to groups given 0 (placebo), 200 or 400 microg oral or vaginal misoprostol 3 h prior to vacuum aspiration. In misoprostol-treated groups the baseline cervical dilatation was significantly increased when compared with the placebo group; the effect was dose-related in the oral but not in the vaginal group. The cumulative force and blood loss was significantly decreased in the misoprostol-treated groups. The incidences of side-effects were more frequent in misoprostol groups but were not related to the route and dosage of medication. The duration of procedure, incidences of post-operative complications, the duration of post-operative bleeding and the interval to the first period were similar in the five treatment groups. We conclude that a 3 h pre-treatment interval is effective for both oral and vaginal routes. When given orally, 400 microg is more effective than 200 microg. The efficacy was otherwise similar when compared with the vaginal route. We recommend 400 microg oral misoprostol 3 h prior to vacuum aspiration for cervical dilatation.Keywords
This publication has 14 references indexed in Scilit:
- An effective regimen for early medical abortion: a report of 2000 consecutive casesHuman Reproduction, 1998
- A comparative study using two dose regimens (200 μg or 400 μg) of vaginal misoprostol for pre‐operative cervical dilatation in first trimester nulliparaeBJOG: An International Journal of Obstetrics & Gynaecology, 1998
- Vaginal misoprostol compared with oral misoprostol in termination of second-trimester pregnancyObstetrics & Gynecology, 1997
- Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised studyBJOG: An International Journal of Obstetrics & Gynaecology, 1996
- A randomised comparison of oral and vaginal misoprostol for cervical priming before suction termination of pregnancyBJOG: An International Journal of Obstetrics & Gynaecology, 1996
- Oral misoprostol versus vaginal gemeprost for cervical dilatation prior to vacuum aspiration in women in the sixth to twelfth week of gestationContraception, 1995
- Pregnancy: Oral misoprostol versus placebo for cervical dilatation before vacuum aspiration in first trimester pregnancyHuman Reproduction, 1995
- Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprostThe Lancet, 1994
- Randomization and the mechanics of treatment masking1986
- Ultrasonic localization of a displaced laminaria tentAmerican Journal of Obstetrics and Gynecology, 1983